Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis
Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as a safe and effective treatment for B-cell l...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
23 October 2024
|
| In: |
American journal of hematology
Year: 2024, Jahrgang: 99, Heft: 12, Pages: 2411-2415 |
| ISSN: | 1096-8652 |
| DOI: | 10.1002/ajh.27505 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ajh.27505 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.27505 
|
| Verfasserangaben: | Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy S. Abramson, Maria Martinez-Lage, Ganesh Shankar, Bryan D. Choi, Jeffrey A. Barnes, Areej El-Jawahri, Ephraim P. Hochberg, P. Connor Johnson, Jacob D. Soumerai, Wolfgang Wick, Marcela V. Maus, Yi-Bin Chen, Matthew J. Frigault, Jorg Dietrich |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1925428419 | ||
| 003 | DE-627 | ||
| 005 | 20250717013342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250512s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ajh.27505 |2 doi | |
| 035 | |a (DE-627)1925428419 | ||
| 035 | |a (DE-599)KXP1925428419 | ||
| 035 | |a (OCoLC)1528045216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kaulen, Leon D. |d 1992- |e VerfasserIn |0 (DE-588)1234159724 |0 (DE-627)1759034819 |4 aut | |
| 245 | 1 | 0 | |a Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis |c Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy S. Abramson, Maria Martinez-Lage, Ganesh Shankar, Bryan D. Choi, Jeffrey A. Barnes, Areej El-Jawahri, Ephraim P. Hochberg, P. Connor Johnson, Jacob D. Soumerai, Wolfgang Wick, Marcela V. Maus, Yi-Bin Chen, Matthew J. Frigault, Jorg Dietrich |
| 264 | 1 | |c 23 October 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.05.2025 | ||
| 520 | |a Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as a safe and effective treatment for B-cell lymphomas. We aimed to assess toxicity and efficacy of CD19-CAR T-cells in neurolymphomatosis. Neurolymphomatosis patients treated with CD19 CAR T-cells were retrospectively identified at Massachusetts General Hospital over a six-year period. Toxicities were graded according to the ASTCT classification, management, and response rates were recorded. Eleven neurolymphomatosis patients were identified with a median of 2 lines of PNS-directed treatments (range: 1-3) prior to receiving CD19-CAR T-cells. Neurolymphomatosis localized to the nerve roots (8/11, 73%), plexus (5/11, 45%), peripheral (4/11, 36%) and cranial nerves (5/11, 45%). Low grade cytokine release syndrome (CRS) was detected in 8/11 (73%; grade 1: N = 7; grade 2: N = 1) cases. Low- and high-grade immune cell-associated neurotoxicity syndrome (ICANS) were recorded in 5/11 (45%; grade 1: N = 4; grade 2: N = 1) and 1/11 (9%; grade 4) patients, respectively. CRP levels at infusion were predictive of ICANS (area under the curve: 0.96, p = 0.01). Seven of eleven neurolymphomatosis patients (64%) responded to CD19-CAR T-cells. Complete remissions (CR) were achieved in three cases (27%), with 2 patients in sustained CR nine and 46 months after CD19-CAR infusion. Median progression-free survival (PFS) was 4 months. Collectively, CD19-CAR T-cell treatment was well tolerated and showed promising efficacy in recurrent neurolymphomatosis, a difficult to treat condition with unmet medical need. Findings suggest that CD19-CAR may sufficiently penetrate the blood-nerve barrier. Toxicity and outcomes were overall similar to CAR-T cell therapy in CNS lymphoma. | ||
| 700 | 1 | |a Karschnia, Philipp |e VerfasserIn |4 aut | |
| 700 | 1 | |a Doubrovinskaia, Sofia |d 1993- |e VerfasserIn |0 (DE-588)1248728602 |0 (DE-627)1784562092 |4 aut | |
| 700 | 1 | |a Abramson, Jeremy S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martinez-Lage, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shankar, Ganesh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Choi, Bryan D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barnes, Jeffrey A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a El-Jawahri, Areej |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hochberg, Ephraim P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Johnson, P. Connor |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soumerai, Jacob D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 700 | 1 | |a Maus, Marcela V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chen, Yi-Bin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frigault, Matthew J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dietrich, Jorg |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d New York, NY : Wiley-Liss, 1976 |g 99(2024), 12 vom: Dez., Seite 2411-2415 |h Online-Ressource |w (DE-627)302923349 |w (DE-600)1492749-4 |w (DE-576)094060002 |x 1096-8652 |7 nnas |a Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis |
| 773 | 1 | 8 | |g volume:99 |g year:2024 |g number:12 |g month:12 |g pages:2411-2415 |g extent:5 |a Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ajh.27505 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.27505 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250512 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 13 | ||
| 998 | |g 1248728602 |a Doubrovinskaia, Sofia |m 1248728602:Doubrovinskaia, Sofia |d 910000 |d 911100 |e 910000PD1248728602 |e 911100PD1248728602 |k 0/910000/ |k 1/910000/911100/ |p 3 | ||
| 998 | |g 1234159724 |a Kaulen, Leon D. |m 1234159724:Kaulen, Leon D. |d 910000 |d 911100 |e 910000PK1234159724 |e 911100PK1234159724 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1925428419 |e 4723701753 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"language":["eng"],"pubHistory":["1.1976 -"],"note":["Gesehen am 19.11.14"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"doi":["10.1002/(ISSN)1096-8652"],"zdb":["1492749-4"],"eki":["302923349"],"issn":["1096-8652"]},"recId":"302923349","origin":[{"publisherPlace":"New York, NY","dateIssuedKey":"1976","dateIssuedDisp":"1976-","publisher":"Wiley-Liss"}],"disp":"Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosisAmerican journal of hematology","title":[{"title_sort":"American journal of hematology","title":"American journal of hematology"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"99","text":"99(2024), 12 vom: Dez., Seite 2411-2415","issue":"12","pages":"2411-2415","year":"2024","extent":"5"}}],"physDesc":[{"noteIll":"Illustrationen","extent":"5 S."}],"title":[{"title":"Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis","title_sort":"Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis"}],"note":["Gesehen am 12.05.2025"],"language":["eng"],"person":[{"given":"Leon D.","display":"Kaulen, Leon D.","family":"Kaulen","role":"aut"},{"family":"Karschnia","role":"aut","display":"Karschnia, Philipp","given":"Philipp"},{"role":"aut","family":"Doubrovinskaia","display":"Doubrovinskaia, Sofia","given":"Sofia"},{"role":"aut","family":"Abramson","display":"Abramson, Jeremy S.","given":"Jeremy S."},{"given":"Maria","display":"Martinez-Lage, Maria","role":"aut","family":"Martinez-Lage"},{"given":"Ganesh","family":"Shankar","role":"aut","display":"Shankar, Ganesh"},{"given":"Bryan D.","role":"aut","family":"Choi","display":"Choi, Bryan D."},{"role":"aut","family":"Barnes","display":"Barnes, Jeffrey A.","given":"Jeffrey A."},{"display":"El-Jawahri, Areej","role":"aut","family":"El-Jawahri","given":"Areej"},{"display":"Hochberg, Ephraim P.","family":"Hochberg","role":"aut","given":"Ephraim P."},{"role":"aut","family":"Johnson","display":"Johnson, P. Connor","given":"P. Connor"},{"role":"aut","family":"Soumerai","display":"Soumerai, Jacob D.","given":"Jacob D."},{"given":"Wolfgang","role":"aut","family":"Wick","display":"Wick, Wolfgang"},{"role":"aut","family":"Maus","display":"Maus, Marcela V.","given":"Marcela V."},{"given":"Yi-Bin","role":"aut","family":"Chen","display":"Chen, Yi-Bin"},{"given":"Matthew J.","family":"Frigault","role":"aut","display":"Frigault, Matthew J."},{"given":"Jorg","family":"Dietrich","role":"aut","display":"Dietrich, Jorg"}],"recId":"1925428419","id":{"eki":["1925428419"],"doi":["10.1002/ajh.27505"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy S. Abramson, Maria Martinez-Lage, Ganesh Shankar, Bryan D. Choi, Jeffrey A. Barnes, Areej El-Jawahri, Ephraim P. Hochberg, P. Connor Johnson, Jacob D. Soumerai, Wolfgang Wick, Marcela V. Maus, Yi-Bin Chen, Matthew J. Frigault, Jorg Dietrich"]},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"23 October 2024"}]} | ||
| SRT | |a KAULENLEONTOXICITIES2320 | ||